Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting

Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting

Background: In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still unclear and no second-line agent has proven its efficacy. Objectives: The aim of this retrospective multicenter real-world cohort study was t...

Full description

Bibliographic Details
Main Authors:	Manon Falette-Puisieux, Jean-Charles Nault, Mohamed Bouattour, Marie Lequoy, Giuliana Amaddeo, Thomas Decaens, Frederic Di Fiore, Sylvain Manfredi, Philippe Merle, Aurore Baron, Christophe Locher, Anna Pellat, Romain Coriat
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-08-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359231189425

Similar Items

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023-08-01)

Downstaging with atezolizumab-bevacizumab: a case series
by: Anand V. Kulkarni, et al.
Published: (2024-09-01)

Pustular psoriasis triggered by therapy with atezolizumab and bevacizumab
by: Mariani Magnus da Luz Andrade, et al.
Published: (2024-01-01)

P-34 ALBUMIN-BILIRUBIN GRADE ANALYSIS OF OVERALL SURVIVAL WITH ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
by: Cristina Cheinquer Coelho Borges, et al.
Published: (2024-12-01)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
by: Takayoshi Suga, et al.
Published: (2023-09-01)

Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies
by: Claudia Campani, et al.
Published: (2024-11-01)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
by: Tomoyuki Satake, et al.
Published: (2023-07-01)

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2023-05-01)

Atezolizumab and Bevacizumab in Therapy for Patients with Hepatocellular Carcinoma in Real Clinical Practice
by: G. A. Serebrennikov, et al.
Published: (2023-07-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma
by: Gabriela Azevedo Solino, et al.
Published: (2023-02-01)

Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
by: Yoshihiko Yano, et al.
Published: (2023-07-01)

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
by: Alessandro Rizzo, et al.
Published: (2021-12-01)

The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß‐catenin signaling
by: Sebastian Krug, et al.
Published: (2022-03-01)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
by: Ali AL Zahrani, et al.
Published: (2021-03-01)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
by: Yukinobu Watanabe MD, PhD, et al.
Published: (2021-11-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
by: Dmitriy Zamarin, et al.
Published: (2020-10-01)

Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
by: Supachaya Sriphoosanaphan, et al.
Published: (2024-01-01)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
by: Sri Harsha Tella, et al.
Published: (2022-06-01)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
by: Kazuhiro Nouso, et al.
Published: (2023-09-01)

Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
by: Young Shin Song, et al.
Published: (2023-05-01)

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
by: Jaekyung Cheon, et al.
Published: (2023-01-01)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
by: Naoto Saito, et al.
Published: (2022-07-01)

Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma
by: D.X. Zhang
Published: (2020-09-01)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024-10-01)

Systemic treatments with tyrosine kinase inhibitor and platinum-based chemotherapy in patients with unresectable or metastatic hepatocholangiocarcinoma
by: Elia Gigante, et al.
Published: (2022-06-01)

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
by: Naoshi Nishida
Published: (2024-10-01)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
by: Hongyu Gong, et al.
Published: (2023-03-01)

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
by: Simon Johannes Gairing, et al.
Published: (2025-03-01)

Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma
by: Ji Yeon Lee, et al.
Published: (2024-07-01)

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
by: Takahiro Kinami, et al.
Published: (2024-03-01)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024-03-01)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023-09-01)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
by: Yasuto Takeuchi, et al.
Published: (2023-09-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
by: Ryosuke Tsunemitsu, et al.
Published: (2023-06-01)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
by: Loïg Gaugain, et al.
Published: (2023-01-01)

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
by: I. А. Dzhanyan, et al.
Published: (2021-06-01)

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab
by: Chiun Hsu, et al.
Published: (2022-08-01)

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2021-02-01)